Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage
The use of activable cell-penetrating peptides (ACPPs) as molecular imaging probes is a promising new approach for the visualization of enzymes. The cell-penetrating function of a polycationic cell-penetrating peptide (CPP) is efficiently blocked by intramolecular electrostatic interactions with a p...
Gespeichert in:
Veröffentlicht in: | International journal of nanomedicine 2012-01, Vol.7, p.1613-1621 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1621 |
---|---|
container_issue | |
container_start_page | 1613 |
container_title | International journal of nanomedicine |
container_volume | 7 |
creator | Shi, Nian-Qiu Gao, Wei Xiang, Bai Qi, Xian-Rong |
description | The use of activable cell-penetrating peptides (ACPPs) as molecular imaging probes is a promising new approach for the visualization of enzymes. The cell-penetrating function of a polycationic cell-penetrating peptide (CPP) is efficiently blocked by intramolecular electrostatic interactions with a polyanionic peptide. Proteolysis of a proteinase-sensitive substrate present between the CPP and polyanionic peptide affords dissociation of both domains and enables the activated CPP to enter cells. This ACPP strategy could also be used to modify antitumor agents for tumor-targeting therapy. Here, we aimed to develop a conjugate of ACPP with antitumor drug doxorubicin (DOX) sensitive to matrix metalloproteinase-2 and -9 (MMP-2/9) for tumor-targeting therapy purposes. The ACPP-DOX conjugate was successfully synthesized. Enzymatic cleavage of ACPP-DOX conjugate by matrix metalloproteinase (MMP)-2/9 indicated that the activation of ACPP-DOX occurred in an enzyme concentration-dependent manner. Flow cytometry and laser confocal microscope studies revealed that the cellular uptake of ACPP-DOX was enhanced after enzymatic-triggered activation and was higher in HT-1080 cells (overexpressed MMPs) than in MCF-7 cells (under-expressed MMPs). The antiproliferative assay showed that ACPP had little toxicity and that ACPP-DOX effectively inhibited HT-1080 cell proliferation. These experiments revealed that the ACPP-DOX conjugate could be triggered by MMP-2/9, which enabled the activated CPP-DOX to enter cells. ACPP-DOX conjugate may be a potential prodrug delivery system used to carry antitumor drugs for MMP-related tumor therapy. |
doi_str_mv | 10.2147/IJN.S30104 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3356196</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2222543034</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-b6c3d01653df228ad95bd271431cc4ab932a680b3d9fad3704a31991848a5533</originalsourceid><addsrcrecordid>eNpVkctO4zAUhq0RowHKbOYBUCR2SKG-5rJBQhWXIjSzgL11Yp-UlNQOTlJRnh5DgQFvbPl85z-Xn5A_jJ5wJvPp_Prvya2gjMofZI-xvEg5ZWLny3uX7Pf9klKVF1n5i-xynrFSsWyPPJy7e3CmcYvEYNuOLYRk7AZ4wMTXCZihWUPV4lsw7dDhEGB4pTvshsZiav2TD2PVRInEeLccFzBgUm0SdM-bVWRNYlqENSzwgPysoe3x9_s9IXcX53ezq_Tm3-V8dnaTGsnokFaZEZayTAlbc16ALVVlec6kYMZIqErBIStoJWxZgxU5lSBYWbJCFqCUEBNyupXtxmqF1qCLPbe6C80KwkZ7aPT3iGvu9cKvtRAqriWLAtOtgPVr7AL2_bfk_7_Gr3SpYqMTcvReMvjHEftBL_0YXBxS83iUFFTISB1vKRN83wesP2UZ1a9O6uik3joZ4cOvU3yiH9aJFzKLnLE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2222543034</pqid></control><display><type>article</type><title>Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>DOVE Medical Press Journals</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Shi, Nian-Qiu ; Gao, Wei ; Xiang, Bai ; Qi, Xian-Rong</creator><creatorcontrib>Shi, Nian-Qiu ; Gao, Wei ; Xiang, Bai ; Qi, Xian-Rong</creatorcontrib><description>The use of activable cell-penetrating peptides (ACPPs) as molecular imaging probes is a promising new approach for the visualization of enzymes. The cell-penetrating function of a polycationic cell-penetrating peptide (CPP) is efficiently blocked by intramolecular electrostatic interactions with a polyanionic peptide. Proteolysis of a proteinase-sensitive substrate present between the CPP and polyanionic peptide affords dissociation of both domains and enables the activated CPP to enter cells. This ACPP strategy could also be used to modify antitumor agents for tumor-targeting therapy. Here, we aimed to develop a conjugate of ACPP with antitumor drug doxorubicin (DOX) sensitive to matrix metalloproteinase-2 and -9 (MMP-2/9) for tumor-targeting therapy purposes. The ACPP-DOX conjugate was successfully synthesized. Enzymatic cleavage of ACPP-DOX conjugate by matrix metalloproteinase (MMP)-2/9 indicated that the activation of ACPP-DOX occurred in an enzyme concentration-dependent manner. Flow cytometry and laser confocal microscope studies revealed that the cellular uptake of ACPP-DOX was enhanced after enzymatic-triggered activation and was higher in HT-1080 cells (overexpressed MMPs) than in MCF-7 cells (under-expressed MMPs). The antiproliferative assay showed that ACPP had little toxicity and that ACPP-DOX effectively inhibited HT-1080 cell proliferation. These experiments revealed that the ACPP-DOX conjugate could be triggered by MMP-2/9, which enabled the activated CPP-DOX to enter cells. ACPP-DOX conjugate may be a potential prodrug delivery system used to carry antitumor drugs for MMP-related tumor therapy.</description><identifier>ISSN: 1178-2013</identifier><identifier>ISSN: 1176-9114</identifier><identifier>EISSN: 1178-2013</identifier><identifier>DOI: 10.2147/IJN.S30104</identifier><identifier>PMID: 22619516</identifier><language>eng</language><publisher>New Zealand: Taylor & Francis Ltd</publisher><subject>Acid Phosphatase ; activable cell-penetrating peptide ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - metabolism ; Antineoplastic Agents - therapeutic use ; antiproliferative ; Biological Transport, Active ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Cell Line, Tumor ; Cell Proliferation - drug effects ; cellular uptake ; Doxorubicin - administration & dosage ; Doxorubicin - metabolism ; Doxorubicin - therapeutic use ; Drug Delivery Systems ; enzymatic cleavage ; Female ; Fibrosarcoma - drug therapy ; Fibrosarcoma - metabolism ; Fibrosarcoma - pathology ; Humans ; matrix metalloproteinase ; Matrix Metalloproteinase 2 - metabolism ; Matrix Metalloproteinase 9 - metabolism ; Nanomedicine ; Original Research ; Peptides ; Protein Tyrosine Phosphatases - administration & dosage ; Protein Tyrosine Phosphatases - metabolism ; proteinase-sensitive substrate ; tumor extracellular environment</subject><ispartof>International journal of nanomedicine, 2012-01, Vol.7, p.1613-1621</ispartof><rights>2012. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2012 Shi et al, publisher and licensee Dove Medical Press Ltd. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-b6c3d01653df228ad95bd271431cc4ab932a680b3d9fad3704a31991848a5533</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356196/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356196/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,862,883,3851,27907,27908,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22619516$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shi, Nian-Qiu</creatorcontrib><creatorcontrib>Gao, Wei</creatorcontrib><creatorcontrib>Xiang, Bai</creatorcontrib><creatorcontrib>Qi, Xian-Rong</creatorcontrib><title>Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage</title><title>International journal of nanomedicine</title><addtitle>Int J Nanomedicine</addtitle><description>The use of activable cell-penetrating peptides (ACPPs) as molecular imaging probes is a promising new approach for the visualization of enzymes. The cell-penetrating function of a polycationic cell-penetrating peptide (CPP) is efficiently blocked by intramolecular electrostatic interactions with a polyanionic peptide. Proteolysis of a proteinase-sensitive substrate present between the CPP and polyanionic peptide affords dissociation of both domains and enables the activated CPP to enter cells. This ACPP strategy could also be used to modify antitumor agents for tumor-targeting therapy. Here, we aimed to develop a conjugate of ACPP with antitumor drug doxorubicin (DOX) sensitive to matrix metalloproteinase-2 and -9 (MMP-2/9) for tumor-targeting therapy purposes. The ACPP-DOX conjugate was successfully synthesized. Enzymatic cleavage of ACPP-DOX conjugate by matrix metalloproteinase (MMP)-2/9 indicated that the activation of ACPP-DOX occurred in an enzyme concentration-dependent manner. Flow cytometry and laser confocal microscope studies revealed that the cellular uptake of ACPP-DOX was enhanced after enzymatic-triggered activation and was higher in HT-1080 cells (overexpressed MMPs) than in MCF-7 cells (under-expressed MMPs). The antiproliferative assay showed that ACPP had little toxicity and that ACPP-DOX effectively inhibited HT-1080 cell proliferation. These experiments revealed that the ACPP-DOX conjugate could be triggered by MMP-2/9, which enabled the activated CPP-DOX to enter cells. ACPP-DOX conjugate may be a potential prodrug delivery system used to carry antitumor drugs for MMP-related tumor therapy.</description><subject>Acid Phosphatase</subject><subject>activable cell-penetrating peptide</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - metabolism</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>antiproliferative</subject><subject>Biological Transport, Active</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>cellular uptake</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - metabolism</subject><subject>Doxorubicin - therapeutic use</subject><subject>Drug Delivery Systems</subject><subject>enzymatic cleavage</subject><subject>Female</subject><subject>Fibrosarcoma - drug therapy</subject><subject>Fibrosarcoma - metabolism</subject><subject>Fibrosarcoma - pathology</subject><subject>Humans</subject><subject>matrix metalloproteinase</subject><subject>Matrix Metalloproteinase 2 - metabolism</subject><subject>Matrix Metalloproteinase 9 - metabolism</subject><subject>Nanomedicine</subject><subject>Original Research</subject><subject>Peptides</subject><subject>Protein Tyrosine Phosphatases - administration & dosage</subject><subject>Protein Tyrosine Phosphatases - metabolism</subject><subject>proteinase-sensitive substrate</subject><subject>tumor extracellular environment</subject><issn>1178-2013</issn><issn>1176-9114</issn><issn>1178-2013</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpVkctO4zAUhq0RowHKbOYBUCR2SKG-5rJBQhWXIjSzgL11Yp-UlNQOTlJRnh5DgQFvbPl85z-Xn5A_jJ5wJvPp_Prvya2gjMofZI-xvEg5ZWLny3uX7Pf9klKVF1n5i-xynrFSsWyPPJy7e3CmcYvEYNuOLYRk7AZ4wMTXCZihWUPV4lsw7dDhEGB4pTvshsZiav2TD2PVRInEeLccFzBgUm0SdM-bVWRNYlqENSzwgPysoe3x9_s9IXcX53ezq_Tm3-V8dnaTGsnokFaZEZayTAlbc16ALVVlec6kYMZIqErBIStoJWxZgxU5lSBYWbJCFqCUEBNyupXtxmqF1qCLPbe6C80KwkZ7aPT3iGvu9cKvtRAqriWLAtOtgPVr7AL2_bfk_7_Gr3SpYqMTcvReMvjHEftBL_0YXBxS83iUFFTISB1vKRN83wesP2UZ1a9O6uik3joZ4cOvU3yiH9aJFzKLnLE</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>Shi, Nian-Qiu</creator><creator>Gao, Wei</creator><creator>Xiang, Bai</creator><creator>Qi, Xian-Rong</creator><general>Taylor & Francis Ltd</general><general>Dove Press</general><general>Dove Medical Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20120101</creationdate><title>Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage</title><author>Shi, Nian-Qiu ; Gao, Wei ; Xiang, Bai ; Qi, Xian-Rong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-b6c3d01653df228ad95bd271431cc4ab932a680b3d9fad3704a31991848a5533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Acid Phosphatase</topic><topic>activable cell-penetrating peptide</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - metabolism</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>antiproliferative</topic><topic>Biological Transport, Active</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>cellular uptake</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - metabolism</topic><topic>Doxorubicin - therapeutic use</topic><topic>Drug Delivery Systems</topic><topic>enzymatic cleavage</topic><topic>Female</topic><topic>Fibrosarcoma - drug therapy</topic><topic>Fibrosarcoma - metabolism</topic><topic>Fibrosarcoma - pathology</topic><topic>Humans</topic><topic>matrix metalloproteinase</topic><topic>Matrix Metalloproteinase 2 - metabolism</topic><topic>Matrix Metalloproteinase 9 - metabolism</topic><topic>Nanomedicine</topic><topic>Original Research</topic><topic>Peptides</topic><topic>Protein Tyrosine Phosphatases - administration & dosage</topic><topic>Protein Tyrosine Phosphatases - metabolism</topic><topic>proteinase-sensitive substrate</topic><topic>tumor extracellular environment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shi, Nian-Qiu</creatorcontrib><creatorcontrib>Gao, Wei</creatorcontrib><creatorcontrib>Xiang, Bai</creatorcontrib><creatorcontrib>Qi, Xian-Rong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of nanomedicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shi, Nian-Qiu</au><au>Gao, Wei</au><au>Xiang, Bai</au><au>Qi, Xian-Rong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage</atitle><jtitle>International journal of nanomedicine</jtitle><addtitle>Int J Nanomedicine</addtitle><date>2012-01-01</date><risdate>2012</risdate><volume>7</volume><spage>1613</spage><epage>1621</epage><pages>1613-1621</pages><issn>1178-2013</issn><issn>1176-9114</issn><eissn>1178-2013</eissn><abstract>The use of activable cell-penetrating peptides (ACPPs) as molecular imaging probes is a promising new approach for the visualization of enzymes. The cell-penetrating function of a polycationic cell-penetrating peptide (CPP) is efficiently blocked by intramolecular electrostatic interactions with a polyanionic peptide. Proteolysis of a proteinase-sensitive substrate present between the CPP and polyanionic peptide affords dissociation of both domains and enables the activated CPP to enter cells. This ACPP strategy could also be used to modify antitumor agents for tumor-targeting therapy. Here, we aimed to develop a conjugate of ACPP with antitumor drug doxorubicin (DOX) sensitive to matrix metalloproteinase-2 and -9 (MMP-2/9) for tumor-targeting therapy purposes. The ACPP-DOX conjugate was successfully synthesized. Enzymatic cleavage of ACPP-DOX conjugate by matrix metalloproteinase (MMP)-2/9 indicated that the activation of ACPP-DOX occurred in an enzyme concentration-dependent manner. Flow cytometry and laser confocal microscope studies revealed that the cellular uptake of ACPP-DOX was enhanced after enzymatic-triggered activation and was higher in HT-1080 cells (overexpressed MMPs) than in MCF-7 cells (under-expressed MMPs). The antiproliferative assay showed that ACPP had little toxicity and that ACPP-DOX effectively inhibited HT-1080 cell proliferation. These experiments revealed that the ACPP-DOX conjugate could be triggered by MMP-2/9, which enabled the activated CPP-DOX to enter cells. ACPP-DOX conjugate may be a potential prodrug delivery system used to carry antitumor drugs for MMP-related tumor therapy.</abstract><cop>New Zealand</cop><pub>Taylor & Francis Ltd</pub><pmid>22619516</pmid><doi>10.2147/IJN.S30104</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1178-2013 |
ispartof | International journal of nanomedicine, 2012-01, Vol.7, p.1613-1621 |
issn | 1178-2013 1176-9114 1178-2013 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3356196 |
source | Taylor & Francis Open Access; MEDLINE; DOVE Medical Press Journals; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
subjects | Acid Phosphatase activable cell-penetrating peptide Antineoplastic Agents - administration & dosage Antineoplastic Agents - metabolism Antineoplastic Agents - therapeutic use antiproliferative Biological Transport, Active Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Cell Line, Tumor Cell Proliferation - drug effects cellular uptake Doxorubicin - administration & dosage Doxorubicin - metabolism Doxorubicin - therapeutic use Drug Delivery Systems enzymatic cleavage Female Fibrosarcoma - drug therapy Fibrosarcoma - metabolism Fibrosarcoma - pathology Humans matrix metalloproteinase Matrix Metalloproteinase 2 - metabolism Matrix Metalloproteinase 9 - metabolism Nanomedicine Original Research Peptides Protein Tyrosine Phosphatases - administration & dosage Protein Tyrosine Phosphatases - metabolism proteinase-sensitive substrate tumor extracellular environment |
title | Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T13%3A30%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhancing%20cellular%20uptake%20of%20activable%20cell-penetrating%20peptide-doxorubicin%20conjugate%20by%20enzymatic%20cleavage&rft.jtitle=International%20journal%20of%20nanomedicine&rft.au=Shi,%20Nian-Qiu&rft.date=2012-01-01&rft.volume=7&rft.spage=1613&rft.epage=1621&rft.pages=1613-1621&rft.issn=1178-2013&rft.eissn=1178-2013&rft_id=info:doi/10.2147/IJN.S30104&rft_dat=%3Cproquest_pubme%3E2222543034%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2222543034&rft_id=info:pmid/22619516&rfr_iscdi=true |